GLP-1受容体作動薬　宝の持ち腐れにしないための本

出版社： フジメディカル出版
著者：
発行日： 2019-10-01
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784862701732
電子書籍版： 2019-10-01 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,300 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,310 円(税込)

購入する

商品紹介

糖尿病薬物治療におけるGLP-1受容体作動薬のポジショニングの再考を，具体的な裏付けを示しながら提言。
基本的解説（種類・分類）から，第一選択薬として用いるべき根拠，膵外作用，基礎インスリンへの上乗せ・ステップダウン，安全性，新規配合注への期待，症例提示まで。
東邦大学の糖尿病・代謝・内分泌学分野の教室の総力を挙げた糖尿病診療に必携の1冊。

目次

  • 1．GLP-1受容体作動薬の基本
    　イントロダクション
    　(1) GLP-1受容体作動薬とは～種類と分類～
    　(2) GLP-1受容体作動薬のわが国における処方状況
    　(3) なぜ，これほど使われなかったかを考えよう

    2．ファーストインジェクションとしてのGLP-1受容体作動薬
    　イントロダクション
    　(1) 注射療法のトレンド，基礎インスリン療法と比較しよう
    　(2) 独り勝ち，最も使われているDPP-4阻害薬と比較しよう　BOOST2

    3．ほかにもたくさんある，GLP-1受容体作動薬を使う理由！
    　イントロダクション
    　(1) GLP-1受容体作動薬の食欲抑制作用について
    　(2) GLP-1受容体作動薬と心血管リスクについて
    　(3) GLP-1受容体作動薬の腎保護作用
    　(4) 糖尿病患者以外に投与したら！（認知症に対する効果，抗肥満薬として）

    4．インスリン療法と絡める
    　イントロダクション
    　(1) 基礎インスリンへの上乗せ
    　(2) 頻回注射療法からのステップダウン
    　(3) 配合薬への期待（IDegLira）

    5．GLP-1受容体作動薬，安全なのか？
    　イントロダクション
    　(1) 低血糖および消化器神経症状
    　(2) 膵炎，悪性腫瘍

    6．症例から考えよう
    　イントロダクション
    　(1) 経口剤との併用
    　(2) 高齢者に在宅で（週1回製剤とデグルデク週3回療法も含めて）
    　(3) 肥満症例（SGLT2阻害薬やメトホルミンと絡めて，三種の神器）
    　(4) インスリンとの併用（離脱，ステップダウン，BOT強化）

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1. GLP - 1受容体作動薬の基本

P.15 掲載の参考文献
1) 日本糖尿病学会編著 : 糖尿病専門医研修ガイドブック 改訂第7版, 東京, 診断と治療社, 2017, pp262-268
 
P.19 掲載の参考文献
1) Li L et al : Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism. Mol Med 17 : 1168-1178, 2011
PubMed
2) Hirata K et al : Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 380 : 44-49, 2009
PubMed
3) Liu H et al : A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 201 : 59-66, 2009
 
4) Marso SP et al : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375 : 311-322, 2016
PubMed
5) Marso SP et al : Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375 : 1834-1844, 2016
PubMed
6) Davies MJ et al : Management of Hyperglycemia in Type2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41 : 2669-2701, 2018
 
P.25 掲載の参考文献
1) Kim YG et al : Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians : a systematic review and meta-analysis. Diabetologia 56 : 696-708, 2013
PubMed
2) Bailey TS et al : Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH) : a randomized, double-blind, double-dummy, activecontrolled 26-week trial. Diabetes Obes Metab 18 : 1191-1198, 2016
PubMed
3) Marso SP et al : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375 : 311-322, 2016
PubMed
4) Marso SP et al : Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375 : 1834-1844, 2016
PubMed
5) Mann JFE et al : Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 377 : 839-848, 2017
PubMed
6) Butler PC et al : A critical analysis of the clinical use of incretin-based therapies : are the GLP-1 therapies safe? Diabetes Care 36 : 2118-2125, 2013
PubMed
7) Faillie JL et al : Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes : cohort study. BMJ 348 : g2780, 2014
PubMed
8) Monami M et al : Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis) : Data from randomized controlled trials. Diabetes Obes Metab 19 : 1233-1241, 2017
 
9) Nakanishi R et al : Attempted suicide with liraglutide overdose did not induce hypoglycemia. Diabetes Res Clin Pract 99 : e3-4, 2013
 
10) Rehfeld JF et al : Cholecystokinin secretion is suppressed by glucagon-like peptide-1 : clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol 53 : 1429-1432, 2018
 

2. ファーストインジェクションとしてのGLP - 1受容体作動薬

P.35 掲載の参考文献
1) Davies MJ et al : Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41 : 2669-2701, 2018
 
2) 日本糖尿病学会編著 : 糖尿病治療ガイド 2018-2019, 東京, 文光堂, 2018
 
3) Singh S et al : Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus : a systematic review and meta-analysis. Diabetes Obes Metab 19 : 228-238, 2017
 
4) Abd El Aziz MS et al : A meta-analysis comparing clinical effects of short- or longacting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 19 : 216-227, 2017
PubMed
5) D'Alessio D et al : Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes Obes Metab 17 : 170-178, 2015
PubMed
6) Diamant M et al : Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3) : an open-label randomised trial. Lancet 375 : 2234-2243, 2010
PubMed
7) Davies MJ et al : Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes : results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 11 : 1153-1162, 2009
PubMed
8) Russell-Jones D et al : Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU) : a randomised controlled trial. Diabetologia 52 : 2046-2055, 2009
 
9) Pratley RE et al : Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7) : a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6 : 275-286, 2018
PubMed
10) Aroda VR et al : Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4) : a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol 5 : 355-366, 2017
PubMed
11) もう手放せない! GLP-1受容体作動薬, 弘世貴久編, 大阪, フジメディカル出版, 2013, pp33-41
 
P.44 掲載の参考文献
1) Seino Y et al : Incretin-based drugs for type 2 diabetes : Focus on East Asian perspectives. J Diabetes Investig 7 (Suppl 1) : 102-109, 2016
 
2) Pratley RE et al : Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin : a 26-week, randomised, parallel-group, open-label trial. Lancet 375 : 1447-1456, 2010
 
3) Yokoyama H et al : Liraglutide Versus Sitagliptin in a 24-week, Multicenter, Open-label, Randomized, Parallel-group Study in Japanese Type 2 Diabetes Mellitus Patients Responding Inadequately to a Sulfonylurea and/or One or Two Other Oral Antidiabetic Drugs (JDDM 33). Jpn Clin Med 5 : 33-41, 2014
 
4) Takeshita Y et al : Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes : A randomized, parallel-group study. J Diabetes Investig 6 : 192-200, 2015
 
5) Miyagi M et al : Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes : A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm. Diabetes Ther 9 : 1959-1968, 2018
PubMed
6) Russell-Jones D et al : Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU) : a randomised controlled trial. Diabetologia 52 : 2046-2055, 2009
 
7) D'Alessio D et al : Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes Obes Metab 17 : 170-178, 2015
PubMed
8) Abd El Aziz MS et al : A meta-analysis comparing clinical effects of short- or longacting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 19 : 216-227, 2017
PubMed
9) Singh S et al : Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus : a systematic review and meta-analysis. Diabetes Obes Metab 19 : 228-238, 2017
 
10) Marso SP et al : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375 : 311-322, 2016
PubMed
11) Marso SP et al : Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375 : 1834-1844, 2016
PubMed
12) Davies MJ et al : Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61 : 2461-2498, 2018
 

3. ほかにもたくさんある, GLP - 1受容体作動薬を使う理由 !

P.49 掲載の参考文献
1) Arakawa M et al : Diabetes 59 : 1030-1037, 2010
PubMed
2) Marso SP et al : N Engl J Med 375 : 311-322, 2016
PubMed
3) Hansen HH et al : J Alzheimers Dis 46 : 877-888, 2015
PubMed
4) Vilsboll T et al : BMJ 344 : d7771, 2012
PubMed
P.55 掲載の参考文献
1) Vilsboll T et al : Effects of glucagon-like peptide-1 receptor agonists on weight loss : systematic review and meta-analyses of randomised controlled trials. BMJ 344 : d7771, 2012
PubMed
2) Fujishima Y et al : Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol 11 : 107, 2012
PubMed
3) 桂田健一, 矢田俊彦 : インクレチンの神経系を介した多様な作用. 最新医学 71 : 37-42, 2016
Medical*Online
4) Sisley S et al : Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest 124 : 2456-2463, 2014
 
5) Secher A et al : The arcuate nucleus mediates GLP-1 receptor agonist liraglutidedependent weight loss. J Clin Invest 124 : 4473-4488, 2014
PubMed
6) Jelsing J et al : Liraglutide : short-lived effect on gastric emptying--long lasting effects on body weight. Diabetes Obes Metab 14 : 531-538, 2012
PubMed
7) Pratley RE et al : Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7) : a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6 : 275-286, 2018
PubMed
P.60 掲載の参考文献
1) American Diabetes Association : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2019 . Diabetes Care 42 (Suppl 1) : S90-S102, 2019
 
2) Marso SP et al ; LEADER Steering Committee ; LEADER Trial Investigators : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375 : 311-322, 2016
 
3) Sorli C et al : Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1) : a double-blind, randomised, placebocontrolled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 5 : 251-260, 2017
PubMed
4) Ahren B et al : Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2) : a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol 5 : 341-354, 2017
PubMed
5) Ahmann AJ et al : Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3) : A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care 41 : 258-266, 2018
PubMed
6) Aroda VR et al : Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4) : a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol 5 : 355-366, 2017
PubMed
7) Rodbard HW et al : Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUTAIN5) : A Randomized, Controlled Trial. J Clin Endocrinol Metab 103 : 2291-2301, 2018
PubMed
8) Marso SP et al ; SUSTAIN-6 Investigators : Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 375 : 1834-1844, 2016
PubMed
9) Pfeffer MA et al ; ELIXA Investigators : Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 373 : 2247-2257, 2015
PubMed
10) Holman RR et al ; EXSCEL Study Group : Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 377 : 1228-1239, 2017
 
11) Gerstein HC et al ; REWIND Investigators : Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) : a double-blind, randomised placebo-controlled trial. Lancet 394 : 121-130, 2019
PubMed
12) Dungan KM et al : Once-weekly dulaglutide versus once-daily liraglutide in metformintreated patients with type 2 diabetes (AWARD-6) : a randomised, open-label, phase 3, noninferiority trial. Lancet 384 : 1349-1357, 2014
PubMed
P.67 掲載の参考文献
1) 日本腎臓学会編 : エビデンスに基づくCKD診療ガイドライン 2018, 東京, 東京医学社, 2018, p104
 
2) 羽田勝計 : 糖尿病性腎症. 医学のあゆみ 252 : 471-477, 2015
Medical*Online
3) Fujita H et al : The protective roles of GLP-1R signaling diabeteic nephropathy : possible mechanism and therapeutic potential. Kidney Int 85 : 579-589, 2014
 
4) Kodera R et al : Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54 : 965-978, 2011
 
5) Mann JFE et al : Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 377 : 839-848, 2017
PubMed
6) Davies MJ et al : Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL) : A Randomized Clinical Trial. Diabetes Care 39 : 222-230, 2016
PubMed
P.74 掲載の参考文献
1) Bullock BP et al : Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137 : 2968-2978, 1996
PubMed
2) Teramoto S et al : Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 31 : 1696-1705, 2011
PubMed
3) 卜部貴夫 : インクレチンの脳保護メカニズム-虚血性脳損傷に対するExendin-4の脳保護作用. 医学のあゆみ 241 : 501-506, 2012
Medical*Online
4) Holscher C : Central effects of GLP-1 : new opportunities for treatments of neurodegenerative disease. J Endocrinol 221 : T31-41, 2014
PubMed
5) Matsuzaki T et al : Insulin resistance is associated with the pathology of Alzheimer disease : the Hisayama study. Neurology 75 : 764-770, 2010
PubMed
6) Bomfim TR et al : An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest 122 : 1339-1353, 2012
 
7) McClean PL, Holscher C : Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology 86 : 241-258, 2014
 
8) Aviles-Olmos I et al : Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 123 : 2730-2736, 2013
PubMed
9) Seino Y et al : Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain : A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 81 : 161-168, 2008
PubMed
10) Pi-Sunyer X et al : A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 373 : 11-22, 2015
 
11) Kadowaki T et al : Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocr J 56 : 415-424, 2009
PubMed
12) Buse JB et al : Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes : An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 29 : 139-153, 2007
PubMed
13) Inagaki N et al : Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug (s) : results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther 34 : 1892-1908, 2012
PubMed
14) Seino Y et al : Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab 14 : 910-917, 2012
PubMed
15) Weinstock RS et al : Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5) : a randomized, phase III study. Diabetes Obes Metab 17 : 849-858, 2015
PubMed
16) Odawara M et al : Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes : 52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab 18 : 249-257, 2016
 
17) Pratley RE et al : Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7) : a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6 : 275-286, 2018
PubMed
18) O'Neil PM et al : Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity : a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 392 : 637-649, 2018
PubMed

4. インスリン療法と絡める

P.83 掲載の参考文献
1) Aroda VR et al : Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors : meta-analysis and systematic review. Clin Ther 34 : 1247-1258.e22, 2012
 
2) 日本糖尿病学会編著 : 糖尿病治療ガイド 2018-2019, 東京, 文光堂, 2018
 
3) Hojberg PV et al : Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52 : 199-207, 2009
PubMed
4) Davies MJ et al : Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41 : 2669-2701, 2018
 
5) Marso SP et al : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375 : 311-322, 2016
PubMed
6) Pfeffer MA et al : Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 373 : 2247-2257, 2015
PubMed
7) Meier JJ et al : Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin : A Randomized, Open-Label Trial. Diabetes Care 38 : 1263-1273, 2015
PubMed
8) Iozzo P et al : Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance. J Clin Endocrinol Metab 84 : 863-868, 1999
 
9) Kurtzhals P et al : Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia 54 : S426, 2011
 
P.90 掲載の参考文献
1) Meier JJ : GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 : 728-742, 2012
 
2) Eng C et al : Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes : a systematic review and meta-analysis. Lancet 384 : 2228-2234, 2014
PubMed
3) 古川慎哉, 酒井武則 : 2型糖尿病における基礎インスリンとリキシセナチド併用療法の有効性および安全性に関する検討 第二報. Pharma Medica 33 : 80-85, 2015
Medical*Online
4) 山下真紀ほか : 強化インスリン療法から基礎インスリンとリキシセナチド併用療法への切り替えに関する検討. Pharma Medica 33 : 84-89, 2015
Medical*Online
5) 中神朋子ほか : 2型糖尿病患者における種々のインスリン療法から持効型溶解インスリンとGLP-1受容体作動薬併用療法への変更の有用性. 東京女子医科大学雑誌 87 (E2) : E175-E181, 2017
 
6) 大工原裕之, 村岡都美江 : 早期糖毒性解除を目指した治療戦略 Basal-Bolus療法から基礎インスリンとリキシセナチドを併用するBPTへのステップダウン. Pharma Medica 33 : 112-117, 2015
Medical*Online
7) Miya A et al : Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy : A randomized controlled trial. J Diabetes Investig 9 : 119-126, 2018
PubMed
8) Yamamoto S et al : Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency : A randomized prospective pilot study. Diabetes Res Clin Pract 140 : 339-346, 2018
PubMed
9) Yoshihara T et al : Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Endocr J 53 : 67-72, 2006
PubMed
10) Kumashiro N et al : Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. Endocr J 54 : 163-166, 2007
PubMed
11) Holman RR et al : 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 : 1577-1589, 2008
PubMed
12) Gerstein HC et al : Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 : 2545-2559, 2008
PubMed
P.96 掲載の参考文献
1) Gough SC et al : Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone : results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2 : 885-893, 2014
PubMed
2) Gough SC et al : One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes : results of a 26-week extension to a 26-week main trial. Diabetes Obes Metab 17 : 965-973, 2015
PubMed
3) Buse JB et al : Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 37 : 2926-2933, 2014
PubMed
4) Linjawi S et al : The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy : DUAL III Randomized Clinical Trial. Diabetes Ther 8 : 101-114, 2017
PubMed
5) Rodbard HW et al : Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes : the DUAL IV trial. Diabet Med 34 : 189-196, 2017
PubMed
6) Lingvay I et al : Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes : The DUAL V Randomized Clinical Trial. JAMA 315 : 898-907, 2016
PubMed
7) Harris SB et al : Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs : DUAL VI randomized clinical trial. Diabetes Obes Metab 19 : 858-865, 2017
 
8) Billings LK et al : Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin : The DUAL VII Randomized Clinical Trial. Diabetes Care 41 : 1009-1016, 2018
PubMed
9) Hojberg PV et al : Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52 : 199-207, 2009
PubMed
10) Lingvay I et al : Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial. Diabetes Obes Metab 20 : 200-205, 2018
PubMed
11) Rodbard HW et al : Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes. Diabetes Obes Metab 18 : 40-48, 2016
PubMed

5. GLP - 1受容体作動薬, 安全なのか ?

P.99 掲載の参考文献
1) Marso SP et al : N Engl J Med 375 : 311-322, 2016
PubMed
2) Marso SP et al : N Engl J Med 375 : 1834-1844, 2016
PubMed
3) Davies MJ et al : Diabetologia 61 : 2461-2498, 2018
PubMed
P.103 掲載の参考文献
1) 日本糖尿病学会編著 : 糖尿病専門医研修ガイドブック 改訂第7版, 東京, 診断と治療社, 2017, p275
 
2) Gareth Williams et al : Handbook of Diabetes, 3rd ed, Blackwell Publishing, Oxford, 2004
 
3) Bremer JP et al : Hypoglycemia unawareness in order compared with middle-aged patients with type 2 diabetes. Diabetes Care 32 : 1513-1517, 2009
 
4) Jaap AJ et al : Perceived symptoms of hypoglycaemia in elderly type 2 diabetic patients treated with insulin. Diabet Med 15 : 398-401, 1998
PubMed
5) Warren RE, Frier BM : Hypoglycemia and cognitive function. Diabetes Obes Metab 7 : 493-503, 2005
PubMed
6) 寺内康夫編著 : ここが知りたいインクレチン関連薬, 東京, 中外医学社, 2013, p72
 
7) Marso SP et al ; LEADER Steering Committee on behalf of the LEADER Trial Investigators : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375 : 311-322, 2016
 
8) Zinman B et al : Hypoglycemia, Cardiovascular Outcomes, and Death : The LEADER Experience. Diabetes Care 41 : 1783-1791, 2018
PubMed
9) Bettge K et al : Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists : A systematic analysis of published clinical trials. Diabetes Obes Metab 19 : 336-347, 2017
 
10) Noguchi Y et al : Signals of gastroesophageal reflux disease caused by incretin-based drugs : a disproportionality analysis using the Japanese adverse drug event report database. J Pharm Health Care Sci 4 : 15, 2018
PubMed
11) 板井進悟ほか : リラグルチドの有害事象による中止の危険因子の探索. 糖尿病 58 : 159-166, 2015
 
12) Madsbad S : Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab 18 : 317-332, 2016
PubMed
13) Buse JB et al ; LEAD-6 Study Group : Liraglutide once a day versus exenatide twice a day for type 2 diabetes : a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374 : 39-47, 2009
 
14) 鈴木吉彦ほか編著 : インクレチン関連薬の臨床, 東京, メディカルトリビューン, 2012, p121
 
P.105 掲載の参考文献
1) Nakayama S et al : Diabetes Care 28 : 227-228, 2005
PubMed
2) Furukawa S et al : Endocr J 59 : 329-333, 2012
PubMed
3) Nakanishi R et al : Diabetes Res Clin Pract 99 : e3-4, 2013
PubMed
P.110 掲載の参考文献
1) Nauck MA, Friedrich N : Do GLP-1-based therapies increase cancer risk? Diabetes Care 36 (Suppl 2) : S245-S252, 2013
 
2) Byrd RA et al : Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor Agonist Dulaglutide in Rodents. Endocrinology 156 : 2417-2428, 2015
 
3) Singh S et al : Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus : a population-based matched case-control study. JAMA Intern Med 173 : 534-539, 2013
PubMed
4) Egan AG et al : Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med 370 : 794-797, 2014
PubMed
5) Azoulay L et al : Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. JAMA Intern Med 176 : 1464-1473, 2016
PubMed
6) Nauck MA et al : Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. Diabetes Care 40 : 647-654, 2017
PubMed
7) Buse JB et al ; for the LEAD-6 Study Group : Liraglutide once a day versus exenatide twice a day for type 2 diabetes : a 26-week randomised, parallel-group, multinational, openlabel trial (LEAD-6). Lancet 374 : 39-47, 2009
 
8) Noel RA et al : Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes : a retrospective cohort study. Diabetes Care 32 : 834-838, 2009
PubMed
9) Elashoff M et al : Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141 : 150-156, 2011
PubMed
10) Thomsen RW et al : Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis : A Nationwide Population-Based Case-Control Study. Diabetes Care 2015 ; 38 : 1089-1098. Diabetes Care 38 : e108-e109, 2015
PubMed
11) Azoulay L et al ; Canadian Network for Observational Drug Effect Studies Investigators : Incretin based drugs and the risk of pancreatic cancer : international multicentre cohort study. BMJ 352 : i581, 2016
 
12) Guo X et al : Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients : A Systematic Review. Clin Drug Investig 36 : 433-441, 2016
PubMed

6. 症例から考えよう

P.119 掲載の参考文献
1) Ferrarini G et al : Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 38 : 1730-1735, 2015
 
2) Nagata T et al : Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 170 : 519-531, 2013
PubMed
3) 矢部大介 : 1. GLP-1受容体作動薬の分類と作用機序, 使用上の注意点. 糖尿病 60 : 562-564, 2017
 
4) von Scholten BJ et al : Glucagon-like peptide 1 receptor agonist (GLP-1 RA) : long-term effect on kidney function in patients with type 2 diabetes. J Diabetes Complications 29 : 670-674, 2015
PubMed
5) Davies MJ et al : Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL) : A Randomized Clinical Trial. Diabetes Care 39 : 222-230, 2016
PubMed
P.127 掲載の参考文献
1) 厚生労働省 : 平成26年国民健康・栄養調査の結果の概要 (https://www.mhlw.go.jp/file/04-Houdouhappyou-10904750-Kenkoukyoku-Gantaisakukenkouzoushinka/0000117311.pdf)
 
2) 日本糖尿病学会・ 日本老年医学会編著 : 高齢者糖尿病治療ガイド 2018, 東京, 文光堂, 2018
 
3) Zinman B et al : Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes : a 16-week, randomised, open-label, phase 2 trial. Lancet 377 : 924-931, 2011
 
4) Zinman B et al : Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes : results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol 1 : 23-31, 2013
 
5) Nagai Y et al : Efficacy and safety of thrice-weekly insulin degludec in elderly patients with type 2 diabetes assessed by continuous glucose monitoring. Endocr J 63 : 1099-1106, 2016
PubMed
6) Noguchi Y et al : Signals of gastroesophageal reflux disease caused by incretin-based drugs : a disproportionality analysis using the Japanese adverse drug event report database. J Pharm Health Care Sci 4 : 15, 2018
PubMed
7) 板井進悟ほか : リラグルチドの有害事象による中止の危険因子の探索. 糖尿病 58 : 159-166, 2015
 
P.133 掲載の参考文献
1) American Diabetes Association : 8. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2018 . Diabetes Care 41 (Suppl 1) : S73-S85, 2018
 
2) American Diabetes Association : 8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care 40 (Suppl 1) : S64-S74, 2017
PubMed
3) Davies MJ et al : Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 41 : 2669-2701, 2018
 
4) Davies MJ et al : Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61 : 2461-2498, 2018
 
5) Results of the liraglutide effect and action in diabetes-evaluation of cardiovascular outcome results (LEADER) trial. Symptoms 3-CT-SY24 at the 76th Scientific Sessions of the American Diabetes Association (ADA). 13 June 2016
 
6) Zinman B et al ; EMPA-REG OUTCOME Investigators : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
7) Rondanelli M et al : Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus. Patient Prefer Adherence 10 : 407-413, 2016
PubMed
8) Pratley RE et al ; SUSTAIN 7 investigators : Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7) : a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6 : 275-286, 2018
PubMed
9) Frias JP et al : Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8) : a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4 : 1004-1016, 2016
 
10) Seino Y et al : Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes : A 52-week, open-label, single-arm study. J Diabetes Investig 9 : 332-340, 2018
PubMed
P.140 掲載の参考文献
1) Abd El Aziz MS et al : A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab 19 : 216-227, 2017
PubMed
2) 石澤香野 : 1. インスリンからGLP-1受容体作動薬への切り替え後に生じた糖尿病ケトアシドーシス (解説). Diabetes Journal 39 : 138-142, 2011
 
3) Kondo Y et al : Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes. J Diabetes Investig 4 : 571-575, 2013
PubMed
4) Usui R et al : Retrospective analysis of safety and efficacy of liraglutide monotherapy and sulfonylurea-combination therapy in Japanese type 2 diabetes : Association of remaining β-cell function and achievement of HbA1c target one year after initiation. J Diabetes Complications 29 : 1203-1210, 2015
 
5) Kawata T et al : Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients? J Clin Med Res 6 : 138-144, 2014
PubMed
6) Mashitani T et al : Patient-reported adherence to insulin regimen is associated with glycemic control among Japanese patients with type 2 diabetes : Diabetes Distress and Care Registry at Tenri (DDCRT 3). Diabetes Res Clin Pract 100 : 189-194, 2013
PubMed
7) Yamamoto S et al : Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency : A randomized prospective pilot study. Diabetes Res Clin Pract 140 : 339-346, 2018
PubMed
8) Eng C et al : Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes : a systematic review and meta-analysis. Lancet 384 : 2228-2234, 2014
PubMed
9) Moller JB et al : Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care 37 : 796-804, 2014
PubMed
10) 日本糖尿病学会編著 : 糖尿病専門医研修ガイドブック 改訂第7版, 東京, 診断と治療社, 2017
 
11) 浜本芳之 : GLP-1受容体作動薬の真の実力とは? ～血糖コントロールを超えたベネフィット～. 日本体質医学会雑誌 79 : 42-46, 2017
 
12) Diamant M et al : Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 37 : 2763-2773, 2014
 

書評

最近チェックした商品履歴

Loading...